Date: 2015-07-27
Type of information: Nomination
Compound:
Company: Keryx Biopharmaceuticals (USA - NY)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 27, 2015, Keryx Biopharmaceuticals announced the appointment of Scott A. Holmes to Chief Financial Officer effective immediately. Mr. Holmes will be responsible for Keryx\'s finance function and will be a member of the company\'s executive team. He will succeed James Oliviero whose planned departure was announced earlier this year. Mr. Oliviero will stay with the company through a transition period. Mr. Holmes brings nearly 20 years of life sciences and financial management expertise to Keryx. He joins the company from AMAG Pharmaceuticals where he most recently served as senior vice president, finance and investor relations during a period of high growth driven by acquisitions and public financings. Prior to AMAG, from 2009 to 2011, he was vice president of finance and treasurer of Molecular Biometrics Inc., a commercial stage medical diagnostics company and vice president of finance & administration of On-Q-ity Inc., an oncology diagnostics company. Prior to 2009, he spent five years at Dynogen Pharmaceuticals, Inc., a privately held pharmaceutical company, where he was vice president finance & administration and treasurer. Earlier in his career, Mr. Holmes served as the controller at Keryx Biopharmaceuticals and was a senior auditor with Ernst & Young, LLP. He earned his Certified Public Accountant certificate in the Commonwealth of Massachusetts and holds a dual M.S/M.B.A degree from Northeastern University Graduate School of Business Administration and B.A. in History from Middlebury College.
Financial terms:
Latest news:
